As shown in Fig. 1F, the key targets of galangin therapy for HCC, including CCNB1, CDK4, CDK1, and PLK1, belong to the cell cycle signaling pathway (hsa04110). The gene discussed is CCNB1; the disease is hepatocellular carcinoma.